Skip to main content
Equibles

AAPG · Ascentage Pharma Group International

Track AAPG — free

Use AAPG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AAPG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.89 +0.53 (+3.45%)
Rebalance outlook locked
Market Cap
$1.45B
Shares
93.39M
Volume · Oct 20 4775 Avg daily vol (3M) 6515

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.92 Open$15.57 Day$15.49–15.92 52W close$14.55–35.46 Avg vol 30d6K Short int9K · 0.0% float · 1.5d Short vol44% Last earningsAug 20, 2026 DataJan 2025–Oct 2026

Up next

Q2 2026 earnings call transcript
call held Aug 20, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-41.5%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-56.7%
Trailing year
Short interest
0.0%
Latest settlement · 1.5 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −3%
below
RSI (14) 53
neutral
MACD trend Positive
52-week position 7%
near low
Momentum
relative strength
Very Weak
1-month return 0%
trailing
6-month return −32%
trailing
YTD return −39%
this year
Relative strength −40%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $16 › 200d $21 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.01% of float · ▼ -53.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 1-yr range
Squeeze score 24
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −64%
past year
ATR 4.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $16 › 200d $21 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.01% of float · ▼ -53.4% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $15 Now $16 · 7% Range high $35
vs 200-day avg -23% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AAPG
Ascentage Pharma Group International
this stock
$1.45B -39.3% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
8
% held
0.0%
Net QoQ
-15.2K sh
Top holder
Point72 Asset Management,…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Falling
Shares short
9.3K
Days to cover
1.5d
Change
-10.6K sh
View
Short Volume
Short vol %
44%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
11
Value
$171
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
41.7%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 15, 2026
This year
35

Ascentage Pharma Group International’s trustee purchased 200,000 existing Shares on-market for the 2022 RSU Scheme on October 15, 2026, bringing total Shares held by the trustee to 2,915,000 Shares.

View
Earnings & Events
Webcasts
Last webcast
Aug 20, 2026
View
Investor Relations
Latest news
Ascentage Pharma to Participate i…
Published
Sep 2, 2026
View

Performance

5D 20D 120D MTD YTD
AAPG +5.7% +0.3% -31.9% -2.4% -39.3%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +6.9% +0.9% -40.0% -3.2% -52.1%
Key facts CIK 2023311 CUSIP 04390B105 Visit website Investor relations